Welcome to our dedicated page for YIELD10 BISCIENCE NEW news (Ticker: YTEN), a resource for investors and traders seeking the latest updates and insights on YIELD10 BISCIENCE NEW stock.
Yield10 Bioscience, Inc. (Nasdaq: YTEN) is a pioneering agricultural bioscience company focusing on the development of cutting-edge technologies for significant improvements in crop yield within the United States and Canada. Founded in 1992 and headquartered in Woburn, Massachusetts, Yield10 leverages advanced genetic engineering to develop high-value traits in seeds, targeting the agriculture and food industries through its Trait Factory. The company has a dedicated oilseed development center in Saskatchewan, Canada.
The core mission of Yield10 is to harness the genetic potential of the oilseed Camelina sativa ('Camelina') for the production of sustainable seed products. These products include feedstock oils for renewable diesel and sustainable aviation biofuels, omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical, and aquafeed applications, and future plans for PHA biomaterials to be used as biodegradable bioplastics.
Yield10’s research initiatives are bolstered by strategic partnerships with industry giants such as Bayer AG for soybean traits, Forage Genetics International, LLC for forage sorghum traits, J. R. Simplot Company for potato traits, and GDM Seeds Inc. for evaluating yield traits in soybeans. These collaborations underscore the company’s commitment to innovation and broadening the impact of its technologies.
Significant recent milestones include the development and successful field testing of proprietary winter Camelina varieties engineered for herbicide tolerance. These varieties showed promising results in tolerating glufosinate and Group 2 herbicides, which are crucial for managing weeds and ensuring high yield in crop rotations across North America. This advancement is expected to facilitate the large-scale adoption of Camelina for biofuel and omega-3 oil markets, with the potential for commercial production as early as 2025.
Regulatory progress has been a key aspect of Yield10’s strategy, with USDA-APHIS determining that its genetically engineered Camelina traits are not subject to certain regulations, allowing for expanded planting and breeding in the United States. Additionally, the Canadian Food Inspection Agency has cleared Yield10's E3902 Camelina, which features enhanced oil production and a lighter seed coat.
Yield10 continues to build on its commercial and regulatory achievements, exemplified by the recent agreement with Vision Bioenergy Oilseeds to license Camelina varieties for biofuel feedstock production. This collaboration aims to support the growing demand for low-carbon intensity feedstock oil, aligning with global decarbonization goals.
For more detailed information about Yield10 Bioscience and its innovative endeavors, visit www.yield10bio.com or follow the company on X (formerly Twitter), Facebook, and LinkedIn.
Yield10 Bioscience, an agricultural bioscience company, will participate in the Benzinga Global Small Cap Conference on May 14, 2021. CEO Oliver Peoples will be featured in a "Fireside Chat" on the Disruptive Innovation track from 12:10 to 12:25 PM EDT. Additionally, he will hold one-on-one meetings with registered investors. An archived replay of the discussion will be available on the conference website. Yield10 focuses on developing superior Camelina varieties and aims to commercialize valuable genetic traits for agriculture.
Yield10 Bioscience (Nasdaq:YTEN) will announce its first quarter 2021 financial results on May 11, 2021. The management will host a conference call at 4:30 p.m. ET to discuss results and corporate updates, followed by a Q&A session. Participants in the U.S. can call 1-877-709-8150 and international callers should dial +1-201-689-8354. A replay will be available an hour after the call until May 25, 2021. Yield10 focuses on developing improved varieties of Camelina for various agricultural applications.
Yield10 Bioscience, an agricultural bioscience company, will present at the Benzinga Biotech Small Cap Conference on March 25, 2021. CEO Oliver Peoples will discuss the company’s innovative initiatives, including their Trait Factory platform aimed at developing improved Camelina varieties. The conference will be held virtually on March 24-25, 2021, and investors can register to attend. An archived presentation will be available post-conference. Yield10's focus is on high-value seed products and licensing traits for major row crops.
Yield10 Bioscience reported its financial results for the year ending December 31, 2020. The company recorded a net loss of $10.2 million, or $4.30 per share, an improvement from a loss of $13.0 million in 2019. Key highlights include a collaboration with Rothamsted Research for omega-3 technology and advancements in CRISPR genome editing for high oil content traits. The company raised $12 million in early 2021 and ended 2020 with $9.7 million in cash. Yield10 plans further development of Camelina varieties to drive growth in omega-3 and bioplastic markets.
Yield10 Bioscience, an agricultural bioscience company, announced that CEO Oliver Peoples will present at Maxim Group’s 2021 Inaugural Emerging Growth Virtual Conference from March 17-19, 2021. Investors can register to view the presentation and request one-on-one meetings with management. Yield10 specializes in developing improved Camelina varieties and discovering valuable genetic traits for agriculture. The company aims to create a high-value seed products business targeting feedstock oils and bioplastics, with a focus on major crops like corn and soybean.
Yield10 Bioscience, Inc. (Nasdaq: YTEN) announced it will report its fourth quarter and full year 2020 financial results on March 16, 2021. A conference call is scheduled for 4:30 p.m. ET, where management will discuss financial results, corporate highlights, and business updates. Investors can participate via phone or a live webcast. A replay will be available until March 30, 2021. Yield10 focuses on developing superior Camelina varieties for agricultural products using its Trait Factory platform, aimed at improving yield traits for major crops.
Yield10 Bioscience, Inc. (Nasdaq: YTEN) will present at the Bank of America 2021 Virtual Global Agriculture & Materials Conference on March 4, 2021. Oliver Peoples, Ph.D., CEO, will discuss the use of Camelina in developing PHA bioplastics during the 7:00 am Eastern Time panel. Additionally, Yield10 management will engage in one-on-one meetings with registered investors. The event highlights the company's significant agricultural innovations and its focus on producing high-value crop varieties for feedstock oils and bioplastics.
Yield10 Bioscience (Nasdaq: YTEN) announced it has raised approximately $3.8 million from the exercise of 472,099 warrants between January 1 and February 16, 2021. The warrants were originally issued in a public offering that closed on November 19, 2019. Overall, since that offering, 679,395 warrants have been exercised, generating a total of $5.4 million. These proceeds will strengthen Yield10's balance sheet and support working capital and corporate purposes.
Yield10 Bioscience, Inc. (Nasdaq: YTEN) has successfully closed its public offering of 1,040,000 shares at a price of $12.25 per share, generating approximately $12.7 million in gross proceeds. The offering included participation from existing investors and was managed by Maxim Group LLC. This public offering was conducted under an effective shelf registration and the final prospectus supplement has been filed with the SEC. Yield10 is focused on agricultural innovations to enhance global food security and sustainability, utilizing its advanced Trait Factory platform.
Yield10 Bioscience, Inc. (Nasdaq: YTEN) has announced the pricing of its underwritten public offering of 1,040,000 shares of common stock at $12.25 per share, totaling approximately $12.7 million in gross proceeds. This offering, available under the company's shelf registration statement, is set to close on February 3, 2021, pending customary conditions. Key investors included Jack W. Schuler and various institutional and retail participants. Maxim Group LLC is the sole book-running manager for this offering.
FAQ
What is the current stock price of YIELD10 BISCIENCE NEW (YTEN)?
What is the market cap of YIELD10 BISCIENCE NEW (YTEN)?
What does Yield10 Bioscience do?
Where is Yield10 Bioscience headquartered?
What are some recent achievements of Yield10 Bioscience?
Who are Yield10 Bioscience’s key partners?
What is Camelina sativa?
What is the significance of Yield10’s herbicide tolerance tests?
What are Yield10’s future plans for Camelina?
What regulatory milestones has Yield10 achieved?
How is Yield10 addressing the demand for omega-3 oils?
Where can I find more information about Yield10 Bioscience?
